Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

IMAAVY™ (nipocalimab-aahu)

Medical Information

Full Prescribing Information (English)

+ Save link

Switching Patients with Generalized Myasthenia Gravis from Other Neonatal Fragment Crystallizable Receptor (FcRn) Blockers to IMAAVY

Last Updated: 04/29/2025

SUMMARY

The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
There is no data available to inform a switch strategy from any other neonatal fragment crystallizable receptor (FcRn) inhibitor to IMAAVY.
Please refer to the local labeling for information on the appropriate use of IMAAVY in patients with generalized myasthenia gravis.

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) conducted on 28 April 2025 did not identify any relevant citations pertaining to this topic.